National Heart and Lung Institute, Imperial College, London, United Kingdom.
J Clin Oncol. 2013 Mar 10;31(8):984-91. doi: 10.1200/JCO.2012.42.7922. Epub 2013 Feb 11.
The anatomic extent of disease, as described by the TNM classification, remains the most powerful prognostic indicator for lung cancer. It is used daily by specialists in all branches of lung cancer care and research. Any new edition of the TNM classification is therefore an important event in the thoracic oncology community and one greeted with mixed feelings. The changes introduced in the seventh edition were the first for 13 years and arguably the most profound since the first data-driven revision more than 40 years earlier. Inevitably there will be concerns that any change in the T, N, or M descriptors and resultant stage groupings will have implications for previous treatment pathways. In this article, the changes to the classification are described, and their possible impacts on clinical care and research are discussed.
肿瘤的解剖学范围，由 TNM 分类来描述，仍然是肺癌最有力的预后指标。它被肺癌治疗和研究各领域的专家每天使用。因此，TNM 分类的任何新版本都是胸肿瘤学界的一个重要事件，也是一个喜忧参半的事件。第七版的变化是 13 年来的第一次，也是自 40 多年前第一次基于数据的修订以来最深刻的一次。不可避免地，人们会担心 T、N 或 M 描述符的任何变化，以及由此产生的分期分组，将对以前的治疗途径产生影响。本文描述了分类的变化，并讨论了它们对临床护理和研究的可能影响。
